Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
Uemura H, Arai G, Uemura H, Suzuki H, Iijima K, Nishimura K, Fujii K, Hatayama T, Aoyama J, Deprince K, Lopez-Gitlitz A, McCarthy S, Larsen JS, Li J, Chi KN. Uemura H, et al. Among authors: nishimura k. Int J Urol. 2021 Mar;28(3):280-287. doi: 10.1111/iju.14447. Epub 2020 Dec 8. Int J Urol. 2021. PMID: 33295007 Clinical Trial.
Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer.
Hatano K, Nishimura K, Nakai Y, Yoshida T, Sato M, Kawashima A, Mukai M, Nagahara A, Uemura M, Oka D, Nakayama M, Takayama H, Shimizu K, Meguro N, Tanigawa T, Yamaguchi S, Tsujimura A, Nonomura N. Hatano K, et al. Among authors: nishimura k. Int J Clin Oncol. 2013 Aug;18(4):704-10. doi: 10.1007/s10147-012-0429-1. Epub 2012 Jun 12. Int J Clin Oncol. 2013. PMID: 22688162 Clinical Trial.
Genetic polymorphisms of CYP17A1 in steroidogenesis pathway are associated with risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapy.
Yamada T, Nakayama M, Shimizu T, Nonen S, Nakai Y, Nishimura K, Fujio Y, Okuyama A, Azuma J, Nonomura N. Yamada T, et al. Among authors: nishimura k. Int J Clin Oncol. 2013 Aug;18(4):711-7. doi: 10.1007/s10147-012-0430-8. Epub 2012 Jun 21. Int J Clin Oncol. 2013. PMID: 22714708
Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
Kawashima A, Tsujimura A, Takayama H, Arai Y, Nin M, Tanigawa G, Uemura M, Nakai Y, Nishimura K, Nonomura N; Osaka Renal Cell Carcinoma Clinical Study Collaboration. Kawashima A, et al. Among authors: nishimura k. Int J Urol. 2012 Dec;19(12):1050-7. doi: 10.1111/j.1442-2042.2012.03115.x. Epub 2012 Aug 5. Int J Urol. 2012. PMID: 22860625
STAT3 polymorphism can predict the response to interferon-α therapy in patients with metastatic renal cell carcinoma.
Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K, Nakamura T, Ogawa O, Naito S; Japan Immunotherapy SNPs-Study Group for Kidney Cancer. Eto M, et al. Among authors: nishimura k. Eur Urol. 2013 Apr;63(4):745-52. doi: 10.1016/j.eururo.2012.09.052. Epub 2012 Sep 28. Eur Urol. 2013. PMID: 23063454 Clinical Trial.
Favorable outcome in elderly Asian patients with metastatic renal cell carcinoma treated with everolimus: the Osaka Urologic Oncology Group.
Inamoto T, Azuma H, Nonomura N, Nakatani T, Matsuda T, Nozawa M, Ueda T, Kinoshita H, Nishimura K, Kanayama HO, Miki T, Tomita Y, Yoshioka T, Tsujihata M, Uemura H. Inamoto T, et al. Among authors: nishimura k. Asian Pac J Cancer Prev. 2014;15(4):1811-5. doi: 10.7314/apjcp.2014.15.4.1811. Asian Pac J Cancer Prev. 2014. PMID: 24641414 Free article.
4,205 results